DLA Piper advises Egis Pharmaceuticals on the acquisition of the second largest dexpanthenol brand in Russia

DLA Piper has advised Hungary-based Egis Pharmaceuticals on its acquisition of the D-Panthenol brand, the second largest brand in the dexpanthenol market in Russia, and of a Russian gynaecology portfolio consisting of Vagilac, Feminal and Folacin brands, from Jadran-Galenski Laboratorij.

Julien Hansen, Corporate partner and Head of the Russia Life Sciences group and the Russia English Law team, commented: "DLA Piper boasts one of the leading life sciences practices in Russia with a truly dedicated and experienced team to handle such complicated transactions. We are delighted to have represented Egis Pharmaceuticals on this matter."

Led by Julien Hansen, DLA Piper's team included Michael Malloy, Intellectual Property counsel, Pavel Arievich, Intellectual Property legal director, and Mukhamed Evloev, Corporate senior associate, of the Moscow office.